BFRI · NASDAQ
Biofrontera (BFRI) Stock Price & Fundamentals
Biofrontera (BFRI) closed at $1,475.82 on Oct 9, 2026, up 0.28% from the previous close of $1,471.67.
Share price, past year
1Y +36.57%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,475.82 |
| Sep 30, 2026 | $1,484.05 |
| Aug 31, 2026 | $1,453.75 |
| Jul 31, 2026 | $1,515.10 |
| Jun 30, 2026 | $1,481.03 |
| May 29, 2026 | $1,429.41 |
| Apr 30, 2026 | $1,375.33 |
| Mar 31, 2026 | $1,337.66 |
| Feb 27, 2026 | $1,353.95 |
| Jan 30, 2026 | $1,346.95 |
| Dec 31, 2025 | $1,229.27 |
| Nov 28, 2025 | $1,175.55 |
| Oct 31, 2025 | $1,143.31 |
Key statistics
- Market cap
- $20.97B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $46.17M
- Net income (TTM)
- −$6.37M
- Shares outstanding
- 14.2M
- Dividend yield
- —
- 52-week range
- $1,080.64 – $1,571.97
Biofrontera's market cap is $20.97B, based on a share price of $1,475.82 and 14.2M shares outstanding as of Jun 30, 2026.
Financials
Biofrontera reported revenue of $41.71M for fiscal 2025, up 11.75% from fiscal 2024.
Biofrontera reported a net loss of $10.54M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 6 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $41.71M | +11.8% | −$10.54M | −25.3% | −$1.04 | −$13.36M |
| FY2024ended Dec 31, 2024 | $37.32M | +9.5% | −$17.76M | −47.6% | −$3.22 | −$10.28M |
| FY2023ended Dec 31, 2023 | $34.07M | +18.8% | −$20.13M | −59.1% | −$13.02 | −$24.90M |
| FY2022ended Dec 31, 2022 | $28.67M | +19.0% | −$640.00K | −2.2% | −$0.61 | −$16.24M |
| FY2021ended Dec 31, 2021 | $24.10M | +27.9% | −$37.71M | −156.5% | — | — |
| FY2020ended Dec 31, 2020 | $18.85M | — | −$10.99M | −58.3% | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $12.00M | −$604.00K | −$0.05 |
| Q1 FY2026ended Mar 31, 2026 | $10.08M | −$4.75M | −$0.41 |
| Q4 FY2025ended Dec 31, 2025 | $17.10M | $5.64M | — |
| Q3 FY2025ended Sep 30, 2025 | $6.99M | −$6.65M | −$0.62 |
| Q2 FY2025ended Jun 30, 2025 | $9.03M | −$5.32M | −$0.57 |
| Q1 FY2025ended Mar 31, 2025 | $8.59M | −$4.20M | −$0.47 |
| Q4 FY2024ended Dec 31, 2024 | $12.56M | −$1.40M | — |
| Q3 FY2024ended Sep 30, 2024 | $9.01M | −$5.67M | −$0.98 |
Company profile
- Name
- Biofrontera Inc.
- Ticker
- BFRI
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 120 Presidential Way,, Suite 330, Woburn, MA 01801
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001858685
Recent SEC filings
- Sep 14, 2026
- Aug 13, 2026
- Aug 13, 2026
- Jul 22, 2026
- Jun 17, 2026
- May 14, 2026
- May 14, 2026
- Mar 19, 2026
Frequently asked questions
What is Biofrontera's stock price?
Biofrontera (BFRI) closed at $1,475.82 on Oct 9, 2026, up 0.28% from the previous close of $1,471.67.
What is Biofrontera's market cap?
Biofrontera's market cap is $20.97B, based on a share price of $1,475.82 and 14.2M shares outstanding as of Jun 30, 2026.
How much revenue does Biofrontera make?
Biofrontera reported revenue of $41.71M for fiscal 2025, up 11.75% from fiscal 2024.
Does Biofrontera pay a dividend?
Biofrontera's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Biofrontera Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures